July 23rd 2025
Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Cardinal Health Report Sees 2022 as “Turning Point” for Biosimilars
February 8th 2022The year 2022 “is set to be a turning point” in the United States, as biosimilars are on their way to delivering $133 billion in aggregate savings by 2025, according to Cardinal Health's “2022 Biosimilars Report: The U.S. Journey and Path Ahead.”
What's Holding Up Biosimilar Uptake? Misconceptions, Misaligned Incentives, Panelists Say
January 26th 2022US biosimilar uptake faces several barriers, including misconceptions regarding biosimilar efficacy and a misalignment of prescription incentives between payers, providers, and patients, panelists discussed.
Phase 3 Study Shows BI Bevacizumab Biosimilar Comparable to Reference Product
January 19th 2022Two biosimilars, Pfizer’s Zirabev and Amgen’s Mvasi, have been approved for indications including unresectable, locally advanced NSCLC and recurrent or metastatic nonsquamous NSCLC. BI 695502 is no longer under development by Boehringer Ingelheim.
Wayne Winegarden, PhD: Why Competition Is Urgently Needed for Enbrel, Humira
December 12th 2021Etanercept and adalimumab biosimilar competition is not only necessary to drive down prices, it’s long overdue, according to Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute.